Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15743877 | 1.00 | EPHX2 (0.47) | EPHX2KDM4EMEN1RECQLKMT2A | |
| SCHEMBL12273911 | 0.94 | ALDH1A1 (0.47) | EPHX2KDM4EMEN1RECQLKMT2A | |
| SCHEMBL5957041 | 0.94 | ALDH1A1 (0.47) | EPHX2KDM4EMEN1RECQLKMT2A | |
| SCHEMBL14695285 | 0.88 | KDM4E (0.44) | EPHX2KDM4EMEN1RECQLKMT2A | |
| SCHEMBL12519105 | 0.88 | KDM4E (0.44) | EPHX2KDM4EMEN1RECQLKMT2A | |
| SCHEMBL14695364 | 0.87 | EPHX2 (0.37) | EPHX2KDM4EMEN1RECQLKMT2A | |
| SCHEMBL12519388 | 0.87 | EPHX2 (0.37) | EPHX2KDM4EMEN1RECQLKMT2A | |
| SCHEMBL5943336 | 0.86 | KDM4E (0.44) | KDM4EMEN1RECQLKMT2AALDH1A1 | |
| SCHEMBL5942243 | 0.86 | ALDH1A1 (0.43) | EPHX2KDM4ECNR2CNR1SMN1; SMN2 | |
| SCHEMBL21711009 | 0.85 | ALDH1A1 (0.44) | EPHX2KDM4ECNR2CNR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-2315740-B1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9708245-B2 | Fatty acid acylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9458094-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160083336-A1 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9272984-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9139516-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9085527-B2 | Fatty acid acylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20120238586-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238756-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238530-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238585-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8173831-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010006085-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | EPHX2 738/4885KDM4E 2493/4885MEN1 4861/4885 |
| US-20120238585-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | EPHX2 738/4885KDM4E 2493/4885MEN1 4861/4885 |
| US-20120238586-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | EPHX2 738/4885KDM4E 2493/4885MEN1 4861/4885 |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | EPHX2 738/4885KDM4E 2493/4885MEN1 4861/4885 |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | EPHX2 738/4885KDM4E 2493/4885MEN1 4861/4885 |
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | EPHX2 738/4885KDM4E 2493/4885MEN1 4861/4885 |
| US-20120238756-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | EPHX2 738/4885KDM4E 2493/4885MEN1 4861/4885 |
| US-20160083336-A1 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES | FADS1, FASN, ALOX5 | EPHX2 564/4885KDM4E 3068/4885MEN1 4776/4885 |
| US-20120238530-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | EPHX2 738/4885KDM4E 2493/4885MEN1 4861/4885 |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | FADS1, FASN, ALOX5 | EPHX2 564/4885KDM4E 3068/4885MEN1 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.